Tools chosen: kalshi_direct claude_news claude_news kalshi_related polymarket_related wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market on Trump making IVF free before Jan 2029. I need the current market anchor, news on Trump's IVF executive orders/policies, related markets, and background on the IVF executive order Trump signed in early 2025.

# Event Will Trump make IVF free (eliminate cost of ≥1 cycle) before Jan 20, 2029? # Outcomes to forecast - **Yes** — Trump takes action eliminating cost of at least one IVF cycle before Jan 20, 2029 - **No** — No such action taken # Kalshi market anchor **KXFREEIVF-29 current YES price: 14%** - 7-day change: **−3%** (drifting down) - 30-day change: flat (0%) - Price range over 151 days: 10%–26% - Volume: ~138 contracts/day (moderate liquidity) Market consensus is firmly bearish and trending slightly lower. # Sub-question answers 1. **Current Kalshi price for KXFREEIVF-29?** — 14% YES, down 3% over 7 days. [Kalshi direct] 2. **Has Trump already eliminated cost of ≥1 IVF cycle?** — No. Actions taken are drug discounts (~$2,200/cycle savings via EMD Serono deal) and voluntary employer benefit pathways — not free IVF. [NBC News, KFF, 19th News Oct 2025] 3. **Status of Feb 2025 EO and follow-ups?** — EO signed Feb 18, 2025 directing policy recommendations only. 90-day deadline missed (May 2025). Oct 2025: 84% drug discount deal + employer guidance announced. Feb 2026: TrumpRx.gov launched. May 2026: proposed rulemaking for voluntary employer "excepted fertility benefits." All voluntary, no mandate. [Federal Register, White House, Prelude Fertility] 4. **Pending federal rules/legislation to make IVF free?** — May 2026 proposed rule (voluntary only). Congressional IVF bills failed in 2024; Health Coverage for IVF Act of 2025 (Rep. Underwood) has no movement. No mandatory coverage framework exists or is on track. [KFF, Segal, Federal Register] 5. **Related prediction markets on Trump IVF?** — No Polymarket market found. No other Kalshi IVF markets with separate signal. [Polymarket scan, Kalshi related] # Key facts (high-confidence, factual) 1. [White House, Feb 2025] EO 14216 directs recommendations on IVF access/cost reduction — no direct mandate or funding 2. [NBCNews, May 2025] 90-day policy recommendation deadline passed with no output from White House 3. [ASRM, Oct 2025] EMD Serono deal provides 84% discount on 3 IVF medications — saves ~$2,200/cycle vs. full IVF cost of $15,000–$25,000 4. [Federal Register, May 2026] Proposed "excepted fertility benefits" rule is voluntary for employers, not a mandate 5. [KFF] No federal law currently mandates insurance coverage for IVF; changing this requires Congressional action 6. [KFF] Senate Republicans blocked national IVF coverage mandates in 2024; political opposition from social conservatives persists 7. [NBCNews] White House met with Catholic Medical Association and USCCB, both opposing IVF promotion 8. [The Hill] DOGE-related HHS layoffs undercut implementation capacity for reproductive medicine initiatives 9. [Wikipedia/Second Trump presidency] Trump signed 225 EOs in 2025; IVF EO was among them but no follow-through on free coverage # Cross-market signals - **Kalshi related:** "Will Trump bring back manufacturing?" at 18.6% — similar "big campaign promise" market trading low; suggests market discounts Trump fulfilling transformative domestic promises - **Polymarket:** No active IVF market found - **Sportsbook implied:** N/A # Analyst opinions and speculation - [KFF, Oct 2025] Actions "fell well short" of campaign promise; voluntary employer pathway reaches only workers at participating employers - [19th News, Oct 2025] "A reversal from remarks Trump made on campaign trail" — Trump promised mandatory insurance coverage; delivered voluntary discounts - [AJMC, Feb 2025] EO "lacks concrete action" and "does not establish new rights or guarantees" - [Segal] Existing ERISA framework cannot compel self-insured plans to cover IVF without new legislation - Social conservative opposition (USCCB, Catholic Medical Association) creates internal political friction against mandating IVF coverage # Directional lean per outcome - **Yes:** Trump has political motivation (pronatalism, campaign promise); some incremental steps taken; TrumpRx.gov and proposed rulemaking show continued engagement; ~2.5 years remain - **No:** All actions to date voluntary/incremental; 90-day deadline missed; congressional path blocked; social conservative opposition; DOGE capacity cuts; market trending down; resolution requires eliminating *all* cost (strict bar), not just discounts # Gaps / unknowns - Whether TrumpRx.gov expands to cover full IVF costs (procedure, not just drugs) - Whether May 2026 proposed rule finalizes with stronger mandatory language - Whether budget reconciliation or executive action could fund a government IVF benefit program - Trump's personal motivation level post-2026 midterms # Calibration anchors - **Kalshi current YES: 14%** (primary anchor) - Analogous "big promise" Kalshi markets (manufacturing revival): 18.6% — similar skepticism - Campaign promises requiring legislation historically fail ~80%+ of the time in single term - Resolution bar is strict: must *eliminate* cost of ≥1 cycle — discounts insufficient - ~2.5 years remain; trajectory is incremental/voluntary, not free **Bottom line:** 14% Kalshi price appears well-calibrated. Evidence strongly supports "No" — all actions taken are voluntary, well short of "free," with no credible mandatory pathway in sight. Slight upside uncertainty from remaining time and Trump's pronatalism rhetoric. Fair estimate: **~12–15% Yes**.

1. Both forecasters under-weighted the strict resolution bar relative to the Kalshi anchor. The brief defines "free" as eliminating cost of ≥1 cycle, yet the most significant action to date (84% drug discount saving ~$2,200 on a $15,000–$25,000 procedure) covers at most ~15% of total cost — a gap so large that even aggressive incremental steps would fall short, suggesting Yes probability closer to or below 10% rather than at/near 14%. 2. Neither forecaster explicitly addressed the missed 90-day EO deadline as a strong negative signal. The brief notes "90-day deadline missed (May 2025)" with no output — this is a concrete data point that the administration lacks internal urgency or capacity, yet both forecasters treat remaining time (2.5 years) as meaningful upside without discounting for this demonstrated follow-through failure. 3. Both forecasts ignore the DOGE/HHS capacity constraint as a compounding barrier. The brief states "DOGE-related HHS layoffs undercut implementation capacity for reproductive medicine initiatives," which not only slows rulemaking but makes a mandatory federal IVF benefit program operationally harder to stand up — a scenario-killer that neither rationale mentions. 4. The social conservative opposition (USCCB, Catholic Medical Association meetings with White House) is cited in the brief but neither forecaster treats it as a near-veto constraint. This internal political friction could block executive action even without congressional obstacles, yet both treat it as a minor factor rather than a potential hard ceiling on Yes probability. 5. Forecast 1 at 10% is plausibly more accurate than Forecast 2 at 13%, but neither adequately justifies why they diverge from the Kalshi anchor in the direction they do — Forecast 1 goes below without explaining what new information justifies undercutting the market, while Forecast 2 essentially restates the anchor without adding analytical value.

9% (50% confidence)

Yes: 9% No: 91%

Strict resolution bar requires eliminating cost of ≥1 full cycle, while best action to date covers ~15% of cost. Missed 90-day EO deadline, DOGE/HHS capacity cuts, congressional blockage, and social conservative opposition compound. Slightly below Kalshi's 14% anchor (which is drifting down) is justified by the strict bar.

Total pipeline time: 106.2s